BEESY Strategy’s Post

🔊 The IMMUNO-model COST ACTION webinar series presents its 2nd Webinar! 👩🏫 Join on May 6, 2024, at 2 pm CET for a discussion on the imSAVAR project with our dedicated researchers Dr. Christina Sakellariou, Dr. Katherina Sewald, and Dr. Marek Ostaszewski. 💻 Register via https://lnkd.in/ddr9KEiW and tune in live on the ZOOM platform for the latest project updates. Don't miss out! #IMMUNOmodel #imSAVAR #Webinar #Immunology #Research #Biotechnology #irAOPs

Today marks Rare Disease Day; a day to focus on social opportunity, healthcare, and access to diagnosis and therapies for people living with a rare disease. At Target ALS, our commitment to realizing a world where #EveryoneLives means we advance research for all people living with ALS, including those with the rarest forms of the disease. Through collaborative efforts with esteemed partners such as n-Lorem Foundation, we are pioneering therapeutic avenues for nano-rare ALS mutations, marking significant progress on a patient-centric trajectory. Together, with aligned organizational core values, we're advancing the frontier of drug discovery tailored to ultra-rare forms of ALS, fueled by a shared philosophy and a concerted mission to drive scientific innovation. #RareDiseaseDay #ALSResearch #ScientificAdvancements #EndALS #RareDisease Sarah Glass, PhD

🔊 Listen to Dr. Mark Murcko in our Inaugural 2024 Kitchen Table Talk! Dewpoint scientists hosted experienced drug-hunter Dr. Mark Murcko to kick off our 2024 Kitchen Table Talk series. Dr. Murcko delves into the evolution of drug discovery strategies and how adopting a condensate mindset can transform the way we develop future therapies. Check out the audiogram below for a glimpse into the discussion, and learn how insights into aberrant #condensates and their relationship to disease are reshaping our understanding of disease mechanisms and strategies for drug discovery. 👉 Watch the full discussion here: https://bit.ly/3VB9Dak #DiscoverCondensates

Today we had a CAR T cell patient testimony, we discussed Challenges in Production, Regulation & Quality Control of C&GT. We discussed the C&GT sector dynamics, market trends, costs, clinical trials & future indications, one example of European hospital exception for CAR T products. So enlightening session !

The greatest excitement I have about this field arises from the potential for transforming #genomicresearch into #clinicalpractice. #clinicalgenetics #clinicalgenomics #genomicmedicine #humangenetics #medicalgenetics #translationalgenomics

Excited to share that my teammates Shoeb Ansari, Dhairya Nathwani and I had the opportunity to present at the national-level article presentation competition, organized by Academic Decipher in collaboration with Dr. L. H. Hiranandani College of Pharmacy. Our topic was 'CRISPR: A Game-Changer for Advanced Drug Targeting in Disease Treatment.' It was a fantastic experience to explore cutting-edge research, and we look forward to the possibility of publishing our work in a research book! #CRISPR #DrugTargeting #ResearchInnovation #PrecisionMedicine

Mitochondrial and inherited metabolic disease taskforce led by Critical Path Institute (C-Path) now has 21 members! We are excited to welcome newest member, The Lily Foundation! The mission of the taskforce is: Standardizing and integrating mitochondrial and inherited metabolic diseases data into the RDCA-DAP®, optimizing clinical trial design and endpoints, and enhancing communication and collaboration among stakeholders, the medical, and research communities to improve the lives of those affected by these diseases. By participating or sharing data with C-Path your data is entrusted to a neutral entity with expertise in data governance, sharing, proper data aggregation and analytics, and working with regulatory bodies. #leighsyndrome #mitochondrialdisease

📹BETWEEN THE LINES: Raj Chovatiya, MD, PhD, MSCI; and Christopher Bunick, MD, PhD, analyze clinical trial data, compare treatment efficacies of upadacitinib and dupilumab, evaluate quality of life measures, and emphasize the importance of translating study results into real-world atopic dermatitis management strategies. Discover expert insights on treatment efficacy and real-world application: https://ow.ly/SyWl50TnjMt

🌍 Rare Diseases: A New Frontier in Innovation 🌐 Global Impact: 350-400 million people worldwide are affected by rare diseases, yet many still lack effective treatments. 🧬 Genetic Roots: 80% of rare diseases are genetic, highlighting the urgent need for advanced therapies. 🚀 ⚠️ Challenges in Development: Small populations and complex trial designs make developing treatments for rare diseases challenging. 🤝 Global Collaboration: Working together across borders is essential for unlocking life-saving treatments for these conditions. At Credevo, we support every step of the journey—from clinical trial design to regulatory approvals. Let’s speed up drug development together! 🌱💡 🔍 Want to learn more? https://lnkd.in/gsTqYtKV #RareDisease #OrphanDrugs #ClinicalTrials #DrugDevelopment #PharmaInnovation #Healthcare

It's #RareDiseaseDay, and we are honored to come together with the rare disease community to raise awareness for people living with a rare disease, their families and caregivers. At Actio, we're pursuing a new approach in genetics-led drug development so that we can offer hope to some of the more than 30 million Americans living with a rare disease. With our expertise in genetics, drug discovery and data sciences, we aim to better understand the underlying causes of rare diseases with high unmet need so that we can bring meaningful, life-changing therapies from one to many. Learn more about rare diseases and how to show your support with #ShowYourStripes and #LightUpForRare at https://lnkd.in/e2nh5pd